

Kevin D Boyd

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4963348/publications.pdf>

Version: 2024-02-01

52
papers

1,707
citations

430442

18
h-index

288905

40
g-index

52
all docs

52
docs citations

52
times ranked

2736
citing authors

#	ARTICLE	IF	CITATIONS
1	A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. <i>Blood</i> , 2010, 116, e56-e65.	0.6	315
2	Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. <i>Blood</i> , 2011, 117, 553-562.	0.6	217
3	Mapping of Chromosome 1p Deletions in Myeloma Identifies <i>FAM46C</i> at 1p12 and <i>CDKN2C</i> at 1p32.3 as Being Genes in Regions Associated with Adverse Survival. <i>Clinical Cancer Research</i> , 2011, 17, 7776-7784.	3.2	147
4	Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome. <i>Clinical Cancer Research</i> , 2010, 16, 1856-1864.	3.2	124
5	Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. <i>Lancet Haematology</i> , 2021, 8, e389-e392.	2.2	121
6	XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. <i>Blood</i> , 2010, 116, 250-253.	0.6	107
7	The impact of extramedullary disease at presentation on the outcome of myeloma. <i>Leukemia and Lymphoma</i> , 2009, 50, 230-235.	0.6	97
8	The potential role of epigenetic therapy in multiple myeloma. <i>British Journal of Haematology</i> , 2010, 148, 702-713.	1.2	60
9	The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 765-774.	1.5	59
10	The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. <i>British Journal of Haematology</i> , 2010, 150, 326-333.	1.2	57
11	Multiple myeloma: an overview of management. <i>Palliative Care and Social Practice</i> , 2019, 13, 117822421986823.	0.6	41
12	Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1703-1707.	1.1	39
13	Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma. <i>British Journal of Haematology</i> , 2012, 156, 552-555.	1.2	33
14	Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results. <i>British Journal of Haematology</i> , 2014, 166, 109-117.	1.2	28
15	High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. <i>Leukemia and Lymphoma</i> , 2010, 51, 2126-2129.	0.6	26
16	Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma. <i>Radiology Imaging Cancer</i> , 2021, 3, e210048.	0.7	22
17	Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2506-2506.	0.8	22
18	Alemtuzumab in the treatment of chronic lymphocytic lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 525-533.	1.1	18

#	ARTICLE	IF	CITATIONS
19	Interobserver agreement of whole-body magnetic resonance imaging is superior to whole-body computed tomography for assessing disease burden in patients with multiple myeloma. <i>European Radiology</i> , 2020, 30, 320-327.	2.3	18
20	Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report. <i>BMC Cancer</i> , 2017, 17, 718.	1.1	16
21	Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial. <i>Haematologica</i> , 2020, Online ahead of print, 0-0.	1.7	16
22	Understanding the molecular biology of myeloma and its therapeutic implications. <i>Expert Review of Hematology</i> , 2012, 5, 603-617.	1.0	14
23	The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a real-world study: the Royal Marsden Hospital experience. <i>Leukemia and Lymphoma</i> , 2017, 58, 494-497.	0.6	14
24	DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 53-54.	0.6	13
25	Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 667-675.	0.2	12
26	Characterising spatial heterogeneity of multiple myeloma in high resolution by whole body magnetic resonance imaging: Towards macro-phenotype driven patient management. <i>Magnetic Resonance Imaging</i> , 2021, 75, 60-64.	1.0	9
27	Novel Drugs in Myeloma: Harnessing Tumour Biology to Treat Myeloma. <i>Recent Results in Cancer Research</i> , 2011, 183, 151-187.	1.8	7
28	Detection of avascular necrosis on routine diffusion-weighted whole body MRI in patients with multiple myeloma. <i>British Journal of Radiology</i> , 2019, 92, 20180822.	1.0	6
29	Inter-observer agreement of baseline whole body MRI in multiple myeloma. <i>Cancer Imaging</i> , 2020, 20, 48.	1.2	6
30	Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone. <i>Blood</i> , 2018, 132, 4482-4482.	0.6	6
31	A real-world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple myeloma patients. <i>British Journal of Haematology</i> , 2020, 191, 927-930.	1.2	5
32	Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd) Tj ETQq0 0 0 rgBT /Overlock 1396-1404.	0.6	5
33	Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy. <i>British Journal of Haematology</i> , 2013, 161, 291-294.	1.2	4
34	Absolute Lymphocyte Count at Day 29 of Treatment Is a Powerful Predictor of Outcome in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 222-226.	0.2	4
35	Liposomal cytarabine in cerebrospinal fluid. <i>British Journal of Haematology</i> , 2009, 145, 679-679.	1.2	3
36	Defining Myeloma Patients at High Risk of Developing Bone Disease While on Bisphosphonate Treatment. <i>Blood</i> , 2010, 116, 782-782.	0.6	3

#	ARTICLE	IF	CITATIONS
37	An analysis of the false negative rate of minimal residual disease measurement by multiparameter flow cytometry in multiple myeloma. International Journal of Laboratory Hematology, 2020, 42, e65-e67.	0.7	2
38	Improving real-world myeloma patient access to whole body MRI through "open-access" knowledge sharing: The UK experience. EJHaem, 2020, 1, 361-363.	0.4	2
39	Durvalumab (DURVA) plus daratumumab (DARA) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2017, 35, TPS8054-TPS8054.	0.8	2
40	Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial. Blood, 2018, 132, 3280-3280.	0.6	2
41	Hypermethylation Is A Key Feature of the Transition of Multiple Myeloma to Plasma Cell Leukemia. Blood, 2010, 116, 535-535.	0.6	1
42	Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); A Report of Second Primary Malignancy (SPM) Rates and the Importance of Review of Reported Cases. Blood, 2015, 126, 1847-1847.	0.6	1
43	Efficacy and side-effect profile of long-term bisphosphonate therapy in patients (pts) with multiple myeloma (MM): MRC myeloma IX study results.. Journal of Clinical Oncology, 2012, 30, 8015-8015.	0.8	1
44	Defining High Risk Myeloma Using Co-Segregating FISH Variables; Results of MRC Myeloma IX. Blood, 2010, 116, 1907-1907.	0.6	1
45	Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial. Blood, 2018, 132, 3274-3274.	0.6	1
46	The genetic and epigenetic mechanisms underlying the behavior of myeloma. , 0, , 48-63.		0
47	B- Cell Chronic Lymphocytic Leukaemia Complicated by Aggressive T-Cell Lymphoma: Clinical and Molecular Analysis of a Rare Variant of Richter's Syndrome.. Blood, 2005, 106, 4999-4999.	0.6	0
48	Autologous Transplantation Is the Optimum Approach to the Management of Myeloma Patients with Extramedullary Disease at Presentation. Blood, 2008, 112, 3313-3313.	0.6	0
49	UTX, a Histone Demethylase, Is Inactivated through Homozygous Deletion, Mutation, and DNA Methylation in Multiple Myeloma.. Blood, 2009, 114, 1798-1798.	0.6	0
50	The Introduction of Novel Agents Improves Outcomes of Young Patients with Myeloma (MM) Treated with Autologous Stem Cell Transplant (ASCT). Blood, 2010, 116, 1348-1348.	0.6	0
51	The Interaction of Response and FISH-Based Risk Stratification to Better Define Clinical Outcome in Myeloma. Blood, 2011, 118, 1823-1823.	0.6	0
52	Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS-mutant Multiple Myeloma. Blood, 2018, 132, 3237-3237.	0.6	0